Qualitek Labs [QLL] vs Dr. Lal PathLabs [LALPATHLAB] Detailed Stock Comparison
Qualitek Labs
BSE
Loading...
Dr. Lal PathLabs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Qualitek Labs wins in 5 metrics, Dr. Lal PathLabs wins in 11 metrics, with 0 ties. Dr. Lal PathLabs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Qualitek Labs | Dr. Lal PathLabs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 45.40 | 55.99 | Qualitek Labs |
| Price-to-Book Ratio | 3.29 | 13.24 | Qualitek Labs |
| Debt-to-Equity Ratio | 37.74 | 7.14 | Dr. Lal PathLabs |
| PEG Ratio | N/A | 2.32 | N/A |
| EV/EBITDA | 22.03 | 40.07 | Qualitek Labs |
| Profit Margin (TTM) | 8.97% | 20.29% | Dr. Lal PathLabs |
| Operating Margin (TTM) | 20.77% | 23.54% | Dr. Lal PathLabs |
| EBITDA Margin (TTM) | 20.77% | 23.54% | Dr. Lal PathLabs |
| Return on Equity | 12.27% | 22.08% | Dr. Lal PathLabs |
| Return on Assets (TTM) | 7.19% | 17.93% | Dr. Lal PathLabs |
| Free Cash Flow (TTM) | $-48.03M | $5.15B | Dr. Lal PathLabs |
| Dividend Yield | N/A | 0.93% | N/A |
| 1-Year Return | -1.65% | 2.15% | Dr. Lal PathLabs |
| Price-to-Sales Ratio (TTM) | 4.56 | 11.39 | Qualitek Labs |
| Enterprise Value | $2.95B | $272.59B | Dr. Lal PathLabs |
| EV/Revenue Ratio | 4.20 | 10.78 | Qualitek Labs |
| Gross Profit Margin (TTM) | N/A | 66.99% | N/A |
| Revenue per Share (TTM) | $79 | $303 | Dr. Lal PathLabs |
| Earnings per Share (Diluted) | $7.07 | $61.63 | Dr. Lal PathLabs |
| Beta (Stock Volatility) | N/A | 0.08 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Qualitek Labs vs Dr. Lal PathLabs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Qualitek Labs | 3.87% | 3.21% | 4.58% | 2.40% | 36.93% | -10.04% |
| Dr. Lal PathLabs | -0.25% | -1.57% | 12.35% | 19.67% | 30.32% | 10.54% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Qualitek Labs | -1.65% | 113.18% | 113.18% | 113.18% | 113.18% | 113.18% |
| Dr. Lal PathLabs | 2.15% | 28.00% | 83.35% | 276.64% | 276.64% | 276.64% |
Performance & Financial Health Analysis: Qualitek Labs vs Dr. Lal PathLabs
| Metric | QLL | LALPATHLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.20B | ₹287.98B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 7,760 | 104,131 |
| 90 Day Avg. Volume | 7,493 | 134,770 |
| Last Close | ₹330.00 | ₹3,374.90 |
| 52 Week Range | ₹215.05 - ₹375.00 | ₹2,293.55 - ₹3,653.95 |
| % from 52W High | -12.00% | -7.64% |
| All-Time High | ₹375.00 (Dec 23, 2024) | ₹4,245.50 (Sep 13, 2021) |
| % from All-Time High | -12.00% | -20.51% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.11% |
| Quarterly Earnings Growth | N/A | 0.24% |
| Financial Health | ||
| Profit Margin (TTM) | 0.09% | 0.20% |
| Operating Margin (TTM) | 0.21% | 0.24% |
| Return on Equity (TTM) | 0.12% | 0.22% |
| Debt to Equity (MRQ) | 37.74 | 7.14 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹97.54 | ₹260.62 |
| Cash per Share (MRQ) | ₹1.99 | ₹139.63 |
| Operating Cash Flow (TTM) | ₹53.16M | ₹4.66B |
| Levered Free Cash Flow (TTM) | ₹76.84M | ₹4.87B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.93% |
| Last 12-Month Dividend | N/A | ₹30.00 |
Valuation & Enterprise Metrics Analysis: Qualitek Labs vs Dr. Lal PathLabs
| Metric | QLL | LALPATHLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 45.40 | 55.99 |
| Forward P/E | N/A | 117.46 |
| PEG Ratio | N/A | 2.32 |
| Price to Sales (TTM) | 4.56 | 11.39 |
| Price to Book (MRQ) | 3.29 | 13.24 |
| Market Capitalization | ||
| Market Capitalization | ₹3.20B | ₹287.98B |
| Enterprise Value | ₹2.95B | ₹272.59B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.20 | 10.78 |
| Enterprise to EBITDA | 22.03 | 40.07 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.08 |
| Book Value per Share (MRQ) | ₹97.54 | ₹260.62 |
Financial Statements Comparison: Qualitek Labs vs Dr. Lal PathLabs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QLL | LALPATHLAB |
|---|---|---|
| Revenue/Sales | N/A | ₹6.70B |
| Cost of Goods Sold | N/A | ₹2.21B |
| Gross Profit | N/A | ₹4.49B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | N/A | ₹1.58B |
| EBITDA | N/A | ₹2.20B |
| Pre-Tax Income | N/A | ₹1.81B |
| Income Tax | N/A | ₹471.00M |
| Net Income (Profit) | N/A | ₹1.34B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QLL | LALPATHLAB |
|---|---|---|
| Cash & Equivalents | ₹51.74M | ₹2.93B |
| Total Current Assets | ₹426.08M | ₹13.64B |
| Total Current Liabilities | ₹325.84M | ₹4.02B |
| Long-Term Debt | ₹308.61M | ₹1.03B |
| Total Shareholders Equity | ₹927.82M | ₹22.06B |
| Retained Earnings | N/A | ₹18.60B |
| Property, Plant & Equipment | ₹589.98M | ₹3.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QLL | LALPATHLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | QLL | LALPATHLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 7,760 | 104,131 |
| Average Daily Volume (90 Day) | 7,493 | 134,770 |
| Shares Outstanding | 9.98M | 83.37M |
| Float Shares | 711,777 | 37.19M |
| % Held by Insiders | 0.69% | 0.57% |
| % Held by Institutions | 0.00% | 0.32% |
Dividend Analysis & Yield Comparison: Qualitek Labs vs Dr. Lal PathLabs
| Metric | QLL | LALPATHLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹30.00 |
| Last 12-Month Dividend Yield | N/A | 0.93% |
| 3-Year Avg Annual Dividend | N/A | ₹20.00 |
| 3-Year Avg Dividend Yield | N/A | 0.28% |
| 3-Year Total Dividends | N/A | ₹60.00 |
| Ex-Dividend Date | N/A | Aug 06, 2025 |